How commercial and medical leaders use mama health to anchor launch decisions in real-world patient evidence — market by market, country by country.
Takeda set out to build a digital companion for psoriasis patients. The team knew the content could not be built from internal hypothesis alone. mama health pressure-tested Takeda's existing patient journey against real patient data — first in Germany, now across five markets — turning a strategic narrative into an operational resource that feeds PsoMate's content pipeline directly.
"What patients said they needed in Berlin is shaping what patients see in Tokyo."
After 22 years in healthcare, I've learned that the real insight lies in the last mile of the patient journey. mama health captures that like never before.
A first-time launch in MG, anchored in patient evidence from market one.
UCB was bringing two new therapies — Zilbrysq and Rystiggo — into a rare neuromuscular condition the team had never marketed in. Italy ran first as a pilot. Personas, biologic adoption insight and the patient journey are now in the hands of the field. The engagement has scaled to a pan-European contract spanning 11 countries, with a unified MG patient journey at leadership level.
What life science partners are unlocking when they build on mama health.
Every customer story on this page follows the same shape. Pilot in one market. Validate the journey. Scale across the portfolio.
Take an existing patient journey, KOL-built or otherwise. Pressure-test it against quantitative data from real patients in the disease.
Where assumption and evidence diverge, the journey is rewritten. KPIs are placed on every stage so stakeholders can plan against it.
Findings carry into commercial, medical and field teams via cross-functional sessions, MSL onboarding, and partner asset integration.
Pilots prove the model. Engagements then expand market by market, with patient voice from each one feeding a single, unified instrument.
Filter by therapy area, region or use case. New engagements added as they become public.